Literature DB >> 11999980

Glycolipid analysis of different tissues and cerebrospinal fluid in type II Gaucher disease.

R Gornati1, B Berra, G Montorfano, C Martini, G Ciana, P Ferrari, M Romano, B Bembi.   

Abstract

The lipid composition or the liver, spleen, brain, cerebellum and cerebrospinal fluid of a Gaucher disease type II patient who died at the age of 5 months was examined. The glycolipid analysis demonstrated a marked increase of total amounts not only in the peripheral tissues but also in the brain cerebellum and cerebrospinal fluid, with a prevalence of glucosylceramide. A reduction in gangliosides was observed in all the analysed tissues with a relative increase of GD3 in the nervous tissue. The fatty acid composition of glucosylceramide showed a prevalence of stearic acid in the central nervous system, while in the peripheral tissues palmitic acid was prevalent. This result suggests a different origin of the glucosylceramide stored in different tissues. The generalized reduction of gangliosides and their modified distribution together with the central nervous system GD3 increment represent a new observation. These data could be useful in the effort to clarify the pathophysiological mechanism of brain damage in neuronopathic Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999980     DOI: 10.1023/a:1015137917508

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  29 in total

1.  METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.

Authors:  R O BRADY; J N KANFER; D SHAPIRO
Journal:  Biochem Biophys Res Commun       Date:  1965-01-18       Impact factor: 3.575

2.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

3.  Intracranial volume change in childhood.

Authors:  S Sgouros; J H Goldin; A D Hockley; M J Wake; K Natarajan
Journal:  J Neurosurg       Date:  1999-10       Impact factor: 5.115

4.  Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.

Authors:  R Schiffmann; M P Heyes; J M Aerts; J M Dambrosia; M C Patterson; T DeGraba; C C Parker; G C Zirzow; K Oliver; G Tedeschi; R O Brady; N W Barton
Journal:  Ann Neurol       Date:  1997-10       Impact factor: 10.422

Review 5.  Enzyme replacement therapy for Gaucher's disease.

Authors:  E Beutler
Journal:  Baillieres Clin Haematol       Date:  1997-12

Review 6.  Gaucher's disease: clinical features and natural history.

Authors:  T M Cox; J P Schofield
Journal:  Baillieres Clin Haematol       Date:  1997-12

7.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Authors:  N W Barton; R O Brady; J M Dambrosia; A M Di Bisceglie; S H Doppelt; S C Hill; H J Mankin; G J Murray; R I Parker; C E Argoff
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

8.  Heterogeneity in the expression pattern of two ganglioside synthase genes during mouse brain development.

Authors:  A Yamamoto; M Haraguchi; S Yamashiro; S Fukumoto; K Furukawa; K Takamiya; M Atsuta; H Shiku; K Furukawa
Journal:  J Neurochem       Date:  1996-01       Impact factor: 5.372

9.  Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease.

Authors:  A Erikson; M Aström; J E Månsson
Journal:  Neuropediatrics       Date:  1995-08       Impact factor: 1.947

10.  Pathological findings in Gaucher disease type 2 patients following enzyme therapy.

Authors:  K E Bove; C Daugherty; G A Grabowski
Journal:  Hum Pathol       Date:  1995-09       Impact factor: 3.466

View more
  8 in total

Review 1.  The pathophysiology of GD - current understanding and rationale for existing and emerging therapeutic approaches.

Authors:  Derralynn A Hughes; Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

2.  Highlighting anatomical sub-structures in rat brain tissue using lipid imaging.

Authors:  Alice M Delvolve; Benoit Colsch; Amina S Woods
Journal:  Anal Methods       Date:  2011-08-01       Impact factor: 2.896

Review 3.  Sphingolipids: the nexus between Gaucher disease and insulin resistance.

Authors:  Maria Fuller
Journal:  Lipids Health Dis       Date:  2010-10-11       Impact factor: 3.876

4.  Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.

Authors:  John Marshall; Jennifer B Nietupski; Hyejung Park; James Cao; Dinesh S Bangari; Cristina Silvescu; Terry Wilper; Kristen Randall; Drew Tietz; Bing Wang; Xiaoyou Ying; John P Leonard; Seng H Cheng
Journal:  Mol Ther       Date:  2019-06-04       Impact factor: 11.454

5.  Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology.

Authors:  Ying Sun; Jane Florer; Christopher N Mayhew; Zhanfeng Jia; Zhiying Zhao; Kui Xu; Huimin Ran; Benjamin Liou; Wujuan Zhang; Kenneth D R Setchell; Jianguo Gu; Gregory A Grabowski
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

Review 6.  Mechanism of Secondary Ganglioside and Lipid Accumulation in Lysosomal Disease.

Authors:  Bernadette Breiden; Konrad Sandhoff
Journal:  Int J Mol Sci       Date:  2020-04-07       Impact factor: 5.923

7.  Substrate compositional variation with tissue/region and Gba1 mutations in mouse models--implications for Gaucher disease.

Authors:  Ying Sun; Wujuan Zhang; You-Hai Xu; Brian Quinn; Nupur Dasgupta; Benjamin Liou; Kenneth D R Setchell; Gregory A Grabowski
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

8.  CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.

Authors:  John Marshall; Ying Sun; Dinesh S Bangari; Eva Budman; Hyejung Park; Jennifer B Nietupski; Amy Allaire; Mary A Cromwell; Bing Wang; Gregory A Grabowski; John P Leonard; Seng H Cheng
Journal:  Mol Ther       Date:  2016-03-07       Impact factor: 11.454

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.